Susana Bizarro

Porto, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival.

ATG16L1 and OPTN as a novel prognostic gene expression signature in acute myeloid leukemia survival.

Journal: Frontiers in oncology

Published: January 09, 2026

Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study.

Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study.

Journal: Hematology, transfusion and cell therapy

Published: August 18, 2024

When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.

When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.

Journal: Current treatment options in oncology

Published: March 16, 2021

Myeloid Disease with the CSF3R T618I Mutation after CLL.

Myeloid Disease with the CSF3R T618I Mutation after CLL.

Journal: Case reports in hematology

Published: October 30, 2020

Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.

Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.

Journal: Cancer genetics

Published: January 12, 2020

Negative MR4·0 chronic myeloid leukaemia and its possible implications for treatment-free remission.

Negative MR4·0 chronic myeloid leukaemia and its possible implications for treatment-free remission.

Journal: British journal of haematology

Published: March 20, 2019

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.

Journal: BMC cancer

Published: July 12, 2018

Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.

Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.

Journal: BMC cancer

Published: June 15, 2018

Diagnosis, complications and management of chronic neutrophilic leukaemia: A case report.

Diagnosis, complications and management of chronic neutrophilic leukaemia: A case report.

Journal: Oncology letters

Published: July 02, 2014

The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry.

The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry.

Journal: Clinical genetics

Published: April 14, 2014

Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.

Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.

Journal: The Journal of molecular diagnostics : JMD

Published: September 20, 2013

POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15).

POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15).

Journal: Molecular cancer

Published: September 12, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026